Evidence map›Paper›PMID 39519037›Full record

ArticleInternational journal of molecular sciences2024

MAD2L2 Dimerization Is Not Essential for Mitotic Regulation.

Nomi Barda, Philippa Jennifer Ayiku, Amit Bar-On, Sahar Movshovitz, Tamar Listovsky

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nomi BardaMolecular Biology Department, Ariel University, Ariel 40700, Israel.
Philippa Jennifer AyikuMolecular Biology Department, Ariel University, Ariel 40700, Israel.ORCID 0009-0002-7188-3712
Amit Bar-OnMolecular Biology Department, Ariel University, Ariel 40700, Israel.
Sahar MovshovitzMolecular Biology Department, Ariel University, Ariel 40700, Israel.
Tamar ListovskyMolecular Biology Department, Ariel University, Ariel 40700, Israel.ORCID 0000-0001-8923-8602

Funding

Ariel University 00000Israel Innovation Authority KAMIN program 79556the Israel Cancer Association 20240106
6 · The paper itself

Abstract

MAD2L2 is a small HORMA domain protein that plays a crucial role in DNA repair and mitosis. In both TLS and shieldin, the dimerization of MAD2L2 via its HORMA domain is critical for the stability and function of these complexes. However, in mitosis, the dimerization state of MAD2L2 remains unknown. To assess the importance of MAD2L2's dimerization during mitosis, we utilized CRISPR/Cas9 to generate MAD2L2 knockout cells, which were subsequently complemented with MAD2L2 species carrying different dimer-disrupting point mutations. We assessed the ability of these MAD2L2 dimer-disrupting mutants to regulate mitosis by evaluating early mitotic events and mitotic fidelity. Our findings indicate that MAD2L2 can function in its monomeric form during mitosis, suggesting that MAD2L2 homodimerization is dispensable for early mitotic regulation. Furthermore, our results suggest that the binding of CDH1 to MAD2L2 is a key regulating factor in mitosis that may actively prevent the formation of MAD2L2 dimers, thereby shifting the cellular balance toward MAD2L2-CDH1 interaction. Thus, the equilibrium between the monomeric and dimeric forms of MAD2L2 is an important cellular factor regulating the MAD2L2-containing complexes.

Indexed as

Mad2 ProteinsMitosisProtein MultimerizationAntigens, CDCadherinsCRISPR-Cas SystemsHEK293 CellsHeLa CellsHumansProtein BindingAntigens, CDCadherinsCDH1 protein, humanMAD2L2 protein, humanMad2 ProteinsMAD2L2mitosisTLS

Identifiers

PMID39519037
PMCPMC11545987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.